Compagnie Lombard Odier SCmA’s Kite Pharma, Inc. KITE Stock Holding History

Compagnie Lombard Odier SCmA’s Portfolio KITE Stock Details KITE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-6,000	Closed	-$269K	–	889
2016 Q4	$269K	Sell	6,000 -2,000	-25%	-$98.1K	0.01%	403
2016 Q3	$447K	Hold	8,000	–	–	0.01%	370
2016 Q2	$400K	Hold	8,000	–	–	0.01%	374
2016 Q1	$367K	Hold	8,000	–	–	0.01%	393
2015 Q4	$493K	Buy	+8,000	New	+$563K	0.02%	322

Other funds holding KITE

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

WCM

Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Compagnie Lombard Odier SCmA's KITE Position: Q1 2017 in Review

Compagnie Lombard Odier SCmA sold out of Kite Pharma, Inc. (KITE) in Q1 2017, closing a stake of 6,000 shares — an estimated $269K sold.

Compagnie Lombard Odier SCmA first reported a position in KITE in Q4 2015 and held it in 5 quarters. The position peaked at $493K in Q4 2015. 209 funds tracked by Wall St. Rank hold KITE as of Q1 2017.

Compagnie Lombard Odier SCmA reported no remaining Kite Pharma, Inc. position as of Q1 2017 after selling out during the quarter.
Compagnie Lombard Odier SCmA sold 6,000 Kite Pharma, Inc. shares in Q1 2017, an estimated $269K.
Compagnie Lombard Odier SCmA first reported a position in Kite Pharma, Inc. in Q4 2015 and held it in 5 quarters.
Compagnie Lombard Odier SCmA's Kite Pharma, Inc. position peaked at $493K in Q4 2015.
209 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q1 2017.

Based on Compagnie Lombard Odier SCmA's 13F filing for Q1 2017, filed 15 May 2017.